Izokibep achieves never-before-seen results in Hidradenitis Suppurativa

California, USA-based immunology specialist Acelyrin has announced data from the open label Part A of a Phase IIb/III trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) that demonstrated treatment with its lead candidate izokibep resulted high orders (HiSCR75 and above) of HiSCR response at 12 weeks, including HiSCR100 responses in 33% of participants, claiming these results are better than any seen before.

HS is a chronic, inflammatory skin disease characterized by abscesses, nodules, fistulae, pain, scarring and malodor, all contributing to a devastating impact on quality of life. The data were presented at the American Academy of Dermatology (AAD) Annual Meeting on March 18, 2023.

While the data are in a relatively small number of patients and lack a placebo-controlled arm, the results suggest additional clinical benefits with izokibep's small molecule size and albumin-binding capabilities – two characteristics in common with sonelokimab from Swiss biotech MoonLake (Nasdaq: MLYX) – in improving penetration and alleviating inflammation in harder-to-target tissues in HS.